Thyroid Hormone Parameters During Cancer Treatment In Children: Results Of The Thyro-Dynamics Study
Journal of Clinical Endocrinology and Metabolism · 07.09.2026
DOI: 10.52338/jocem.2026.6072 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Endocrinology and Metabolism, online erschienen am 07.09.2026. Verfasst von Stephanie van der Leij und 8 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Context
Thyroid dysfunction is a well-known late effect of child cancer survivors, but its prevalence during childhood cancer treatment remains unclear.
Objective
To prospectively study the prevalence of thyroid dysfunction and changes in thyroid hormone parameters during childhood cancer treatment, including its effect on height and weight.
Design
Thyroid hormone parameters were prospectively collected at four time points in children with newly diagnosed cancer at the Princess Máxima Center during and shortly after systemic antineoplastic therapy.
Participants
286 children diagnosed with leukemia, lymphoma, sarcoma, or a brain tumor (not involving the hypothalamic–pituitary region) were included. Main outcomes: Prevalence of primary thyroid dysfunction and changes in thyroid function parameters.
Results
None of the included patients developed overt primary hypothyroidism. Subclinical hypothyroidism was present in 8.2% (18/219) at diagnosis, in 2.9% (8/275) three months after diagnosis and in 5.3% (9/171) post-therapy. Non thyroidal illness (NTI) was found in 1.5% (4/265) of children, three months after start of treatment. However elevated concentrations of reverse T3 (rT3) were observed in 31.5% (46/146) at diagnosis, in 46.4% (123/265) at three months, and in 41% (25/61) three months posttherapy. In 27.7% (54/195) of patients, FT4 declined ≥20 % from start to three months after diagnosis and persisted until the end of therapy in 30.2% (13/43). Linear growth and BMI were unaffected by an FT4 decline ≥20%.
Conclusion
Children currently treated for cancer have low risk of primary thyroid dysfunction or NTI during treatment. Although changes in thyroid hormone parameters are common, they do not seem to influence linear growth or BMI.
Zitieren
APA
Leij, S. V. D., Lebbink, C. A., Fiocco, M., Dierselhuis, M. P., Plasschaert, S. L. A., Stuart, A. A. V., Sande, J. V. D., Tissing, W. J. E., & Santen, H. M. V. (2026). Thyroid Hormone Parameters During Cancer Treatment In Children: Results Of The Thyro-Dynamics Study. Journal of Clinical Endocrinology and Metabolism. https://doi.org/10.52338/jocem.2026.6072
Vancouver
Leij SVD, Lebbink CA, Fiocco M, Dierselhuis MP, Plasschaert SLA, Stuart AAV, et al. Thyroid Hormone Parameters During Cancer Treatment In Children: Results Of The Thyro-Dynamics Study. Journal of Clinical Endocrinology and Metabolism. 2026. doi:10.52338/jocem.2026.6072
BibTeX
@article{Leij2026,
author = {Leij, Stephanie van der and Lebbink, Chantal A. and Fiocco, Marta and Dierselhuis, Miranda P. and Plasschaert, Sabine L. A. and Stuart, Annemarie A. Verrijn and Sande, Jasmijn van de and Tissing, Wim J. E. and Santen, Hanneke M. van},
title = {Thyroid Hormone Parameters During Cancer Treatment In Children: Results Of The Thyro-Dynamics Study},
journal = {Journal of Clinical Endocrinology and Metabolism},
year = {2026},
doi = {10.52338/jocem.2026.6072}
}
EUVIMED